ECSP12011908A - OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO - Google Patents
OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMOInfo
- Publication number
- ECSP12011908A ECSP12011908A ECSP12011908A ECSP12011908A EC SP12011908 A ECSP12011908 A EC SP12011908A EC SP12011908 A ECSP12011908 A EC SP12011908A EC SP12011908 A ECSP12011908 A EC SP12011908A
- Authority
- EC
- Ecuador
- Prior art keywords
- pirrolos
- octahidropirrolo
- disustituidos
- useful
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen compuestos de octahidropirrolo[3,4-c]pirrol disustituidos, que son útiles como moduladores del receptor de orexina. Tales compuestos pueden ser útiles en composiciones farmacéuticas y en los métodos para el tratamiento de estados de enfermedad, trastornos, y afecciones mediadas por la actividad de la orexina, tal como el insomnio.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25450909P | 2009-10-23 | 2009-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12011908A true ECSP12011908A (es) | 2012-07-31 |
Family
ID=43385633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12011908 ECSP12011908A (es) | 2009-10-23 | 2012-05-17 | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO |
Country Status (38)
Country | Link |
---|---|
US (8) | US8653263B2 (es) |
EP (3) | EP2491038B1 (es) |
JP (1) | JP5759470B2 (es) |
KR (3) | KR101859400B1 (es) |
CN (1) | CN102781942B (es) |
AR (2) | AR078731A1 (es) |
AU (2) | AU2010310595B2 (es) |
BR (1) | BR112012010820B1 (es) |
CA (1) | CA2778484C (es) |
CL (1) | CL2010001162A1 (es) |
CO (1) | CO6541572A2 (es) |
CR (1) | CR20120273A (es) |
CY (2) | CY1117743T1 (es) |
DK (2) | DK2491038T3 (es) |
EA (1) | EA022766B1 (es) |
EC (1) | ECSP12011908A (es) |
ES (2) | ES2735411T3 (es) |
HK (2) | HK1175463A1 (es) |
HR (2) | HRP20160781T1 (es) |
HU (2) | HUE028650T2 (es) |
IL (1) | IL219234A (es) |
JO (2) | JO3267B1 (es) |
LT (1) | LT3093291T (es) |
ME (2) | ME02437B (es) |
MX (1) | MX2012004753A (es) |
NI (1) | NI201200062A (es) |
NZ (1) | NZ599629A (es) |
PE (1) | PE20110404A1 (es) |
PL (2) | PL2491038T3 (es) |
PT (2) | PT3093291T (es) |
RS (2) | RS54945B1 (es) |
SI (2) | SI2491038T1 (es) |
SM (1) | SMT201600216B (es) |
TR (1) | TR201910327T4 (es) |
TW (1) | TWI481613B (es) |
UA (1) | UA107812C2 (es) |
UY (1) | UY32966A (es) |
WO (1) | WO2011050198A1 (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2735411T3 (es) | 2009-10-23 | 2019-12-18 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina |
WO2012145581A1 (en) * | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
US8501768B2 (en) * | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
WO2013068935A1 (en) | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
EP2811997B1 (en) | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
TWI570120B (zh) | 2012-06-04 | 2017-02-11 | 艾克泰聯製藥有限公司 | 苯并咪唑脯胺酸衍生物 |
JP6254163B2 (ja) * | 2012-08-16 | 2017-12-27 | ザ スクリプス リサーチ インスティテュート | 新規カッパオピオイドリガンド |
CA2885180C (en) | 2012-10-10 | 2021-03-02 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
CN103012293A (zh) * | 2012-12-13 | 2013-04-03 | 同济大学 | 一种抗失眠药物mk-4305中间体的合成方法 |
CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
TW201444849A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
EP3016653A4 (en) * | 2013-07-03 | 2017-02-22 | Abide Therapeutics, Inc. | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof |
CN105873921B (zh) | 2013-12-04 | 2019-03-15 | 爱杜西亚药品有限公司 | 苯并咪唑-脯氨酸衍生物的用途 |
WO2016020403A1 (en) * | 2014-08-04 | 2016-02-11 | Sandoz Ag | Preparation of a benzoic acid derivative and its use for the preparation of suvorexant |
WO2016025669A1 (en) | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
CA2960791C (en) | 2014-09-11 | 2023-03-14 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
CN106349228B (zh) | 2015-07-17 | 2019-07-09 | 广东东阳光药业有限公司 | 取代的喹唑啉酮类化合物及其制备方法和用途 |
AU2016360245B2 (en) * | 2015-11-23 | 2020-07-09 | Sunshine Lake Pharma Co., Ltd. | Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof |
WO2017088731A1 (zh) * | 2015-11-24 | 2017-06-01 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
CA3013927C (en) | 2016-02-12 | 2024-02-13 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
MA43468B1 (fr) | 2016-03-10 | 2020-08-31 | Janssen Pharmaceutica Nv | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 |
WO2017197192A1 (en) | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
CN105949203B (zh) * | 2016-05-24 | 2018-07-13 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途 |
CN107759620B (zh) * | 2016-08-16 | 2021-11-12 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其使用方法和用途 |
JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
CN108299437B (zh) * | 2017-01-13 | 2022-07-08 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
GB201702174D0 (en) * | 2017-02-09 | 2017-03-29 | Benevolentai Bio Ltd | Orexin receptor antagonists |
PL3619199T3 (pl) | 2017-05-03 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)-benzoesowego |
GB201707504D0 (en) * | 2017-05-10 | 2017-06-21 | Benevolentai Bio Ltd | Orexin receptor antagonists |
GB201707499D0 (en) * | 2017-05-10 | 2017-06-21 | Benevolentai Bio Ltd | Orexin receptor antagonists |
KR20200046061A (ko) | 2017-08-29 | 2020-05-06 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 |
EP3675848B1 (en) | 2017-08-29 | 2022-03-23 | H. Lundbeck A/S | Spirocycle compounds and methods of making and using same |
EP3668864B1 (en) | 2017-09-28 | 2021-07-21 | Boehringer Ingelheim International GmbH | N-(2,2-difluoroethyl)-n-[(pyrimidinylamino)propanyl]arylcarboxamides |
CN109988170B (zh) * | 2017-12-29 | 2022-04-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
CN109988171A (zh) * | 2017-12-29 | 2019-07-09 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
CN109988169B (zh) * | 2017-12-29 | 2022-02-01 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物及其用途 |
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
WO2020023723A1 (en) * | 2018-07-27 | 2020-01-30 | Icahn School Of Medicine At Mount Sinai | Method of treating aggression with orexin receptor antagonists |
WO2020100011A1 (en) * | 2018-11-14 | 2020-05-22 | Janssen Pharmaceutica Nv | Improved synthetic methods of making fused heterocyclic compounds as orexin receptor modulators |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
CN112142713A (zh) * | 2019-06-27 | 2020-12-29 | 山东润博生物科技有限公司 | 一种咪草烟的合成方法 |
EP4010325A1 (en) * | 2019-08-07 | 2022-06-15 | Janssen Pharmaceutica NV | Improved synthetic methods of making (2h-1,2,3-triazol-2-yl)phenyl compounds as orexin receptor modulators |
CN112876478B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
CN112876480B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
WO2021104294A1 (en) * | 2019-11-29 | 2021-06-03 | Sunshine Lake Pharma Co., Ltd. | CRYSTAL FORMS OF OCTAHYDROPYRROLO [3,4-c] PYRROLE DERIVATIVES |
CN112876481B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
CN112876479B (zh) * | 2019-11-29 | 2022-07-26 | 广东东阳光药业有限公司 | 八氢吡咯并[3,4-c]吡咯衍生物的晶型 |
WO2022122009A1 (zh) * | 2020-12-11 | 2022-06-16 | 苏州晶云药物科技股份有限公司 | 吡咯类衍生化合物的晶型及其制备方法 |
EP4310089A1 (en) * | 2021-03-16 | 2024-01-24 | Shanghai Hansoh Biomedical Co., Ltd. | Nitrogen-containing heterocyclic polycyclic compound, preparation method therefor, and application thereof |
CN114063673B (zh) * | 2021-11-09 | 2023-03-03 | 万华化学集团股份有限公司 | 一种反应釜温度控制方法、***及存储介质 |
WO2023163964A1 (en) | 2022-02-24 | 2023-08-31 | Teva Czech Industries S.R.O. | Solid state forms of seltorexant |
WO2023180556A1 (en) | 2022-03-24 | 2023-09-28 | Janssen Pharmaceutica Nv | Methods for treating agitation in subjects with mild cognitive impairment or major neurocognition disorder |
WO2024015503A1 (en) * | 2022-07-15 | 2024-01-18 | Biogen Ma Inc. | Emopamil-binding protein inhibitors and uses thereof |
WO2024056016A1 (zh) * | 2022-09-14 | 2024-03-21 | 江苏豪森药业集团有限公司 | 含氮杂环的多环化合物的自由碱晶型及其制备方法 |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7503310A (nl) | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
GB1526331A (en) | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
WO1996039407A1 (en) | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
WO2000055143A1 (en) | 1999-03-17 | 2000-09-21 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
US6375897B1 (en) | 2000-02-14 | 2002-04-23 | Ansys Technologies, Inc. | Urine collection cup |
US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
WO2001085693A1 (fr) | 2000-05-11 | 2001-11-15 | Banyu Pharmaceutical Co., Ltd. | Dérivés n-acyltétrahydroisoquinoline |
SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
WO2002070527A1 (en) | 2001-03-02 | 2002-09-12 | Akzo Nobel N.V. | Mass-selective purification of organometallics |
JP2004529113A (ja) | 2001-03-07 | 2004-09-24 | ファイザー・プロダクツ・インク | ケモカイン受容体活性のモジュレーター |
JP4399256B2 (ja) | 2001-06-28 | 2010-01-13 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体アンタゴニストとしてのn−アロイル環状アミン誘導体 |
US6455722B1 (en) | 2001-06-29 | 2002-09-24 | Pabu Services, Inc. | Process for the production of pentaerythritol phosphate alcohol |
GB2383315B (en) | 2001-12-18 | 2005-04-06 | Christopher Donald Clarke | Vehicle imaging system |
GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
DE10226943A1 (de) | 2002-06-17 | 2004-01-08 | Bayer Ag | Phenylaminopyrimidine und ihre Verwendung |
ES2278197T3 (es) * | 2002-07-09 | 2007-08-01 | Actelion Pharmaceuticals Ltd. | Derivados de 7,8,9,10-tetrahidro-6h-azepino, 6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo(1,2-b)-quinazolinona. |
DE60335891D1 (de) | 2002-10-11 | 2011-03-10 | Actelion Pharmaceuticals Ltd | Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste |
GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
MXPA05010137A (es) | 2003-03-26 | 2005-11-16 | Actelion Pharmaceuticals Ltd | Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina. |
CA2520839A1 (en) | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Quinoxalinone-3- one derivatives as orexin receptor antagonists |
US20040242641A1 (en) | 2003-05-27 | 2004-12-02 | Buckley Michael J. | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
WO2005005439A1 (en) | 2003-07-09 | 2005-01-20 | Suven Life Sciences Limited | Benzothiazino indoles |
TW200507850A (en) | 2003-07-25 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
WO2005023231A1 (en) | 2003-09-10 | 2005-03-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis |
US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
EP1691811B1 (en) | 2003-12-11 | 2014-07-23 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
PT1751111E (pt) | 2004-03-01 | 2015-04-01 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina substituída |
US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
AU2005219438B2 (en) | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
CN101065385A (zh) | 2004-07-22 | 2007-10-31 | 坎布里制药公司 | 治疗微生物感染的利福霉素衍生物 |
WO2006012396A1 (en) | 2004-07-22 | 2006-02-02 | Glaxo Group Limited | Antibacterial agents |
FR2874011B1 (fr) | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
CA2579227A1 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Arylalkyl ureas as cb1 antagonists |
JP2008520644A (ja) | 2004-11-24 | 2008-06-19 | ファイザー・インク | オクタヒドロピロロ[3,4−c]ピロール誘導体 |
DE102004061344A1 (de) | 2004-12-20 | 2006-07-06 | Siemens Ag | Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software |
MX2007013986A (es) * | 2005-05-13 | 2008-02-22 | Lexicon Pharmaceuticals Inc | Compuestos multiciclicos y metodos para su uso. |
US20060258691A1 (en) | 2005-05-13 | 2006-11-16 | Joseph Barbosa | Methods and compositions for improving cognition |
GB0510204D0 (en) * | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
US20080175795A1 (en) | 2005-06-30 | 2008-07-24 | Bexel Pharmaceuticals, Inc. | Novel derivatives of amino acids for treatment of obesity and related disorders |
GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
WO2007025069A2 (en) | 2005-08-26 | 2007-03-01 | Merck & Co., Inc. | Diazaspirodecane orexin receptor antagonists |
FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
AU2007245037A1 (en) | 2006-03-29 | 2007-11-08 | Merck Sharp & Dohme Corp. | Diazepan orexin receptor antagonists |
US20090105318A1 (en) | 2006-03-29 | 2009-04-23 | Coleman Paul J | Amidoethylthioether Orexin Receptor Antagonists |
US7834028B2 (en) | 2006-04-26 | 2010-11-16 | Actelion Pharmaceuticals Ltd. | Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists |
WO2007146761A2 (en) | 2006-06-12 | 2007-12-21 | Neurogen Corporation | Diaryl pyrimidinones and related compounds |
EP2049529B1 (en) * | 2006-07-14 | 2010-08-11 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
JP2009543790A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 2−置換プロリンビス−アミドオレキシン受容体アンタゴニスト |
AU2007272854B2 (en) | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
RU2447070C2 (ru) | 2006-08-15 | 2012-04-10 | Актелион Фармасьютиклз Лтд | Соединения азетидина в качестве антагонистов рецептора орексина |
CN101511833A (zh) | 2006-08-28 | 2009-08-19 | 埃科特莱茵药品有限公司 | 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物 |
ES2345130T3 (es) | 2006-09-18 | 2010-09-15 | F. Hoffmann-La Roche Ag | Derivados de octahidropirrolo(3,4-c)pirrol y su uso como antiviricos. |
EP2079690B1 (en) | 2006-09-29 | 2010-09-15 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.1.0]hexane derivatives |
US20100105614A1 (en) | 2006-10-25 | 2010-04-29 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
EP2089018A2 (en) | 2006-11-07 | 2009-08-19 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
US20110077200A1 (en) | 2006-12-06 | 2011-03-31 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
EP2125823B1 (en) | 2006-12-22 | 2012-02-15 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
JP2010525077A (ja) | 2007-04-25 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 非塩基性メラニン凝集ホルモン受容体−1アンタゴニスト |
US8263586B2 (en) | 2007-05-18 | 2012-09-11 | Merck Sharp & Dohme Corp. | OXO bridged diazepan orexin receptor antagonists |
FR2918061B1 (fr) * | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
US20090022670A1 (en) | 2007-07-03 | 2009-01-22 | Giuseppe Alvaro | Novel compounds |
CA2691373A1 (en) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
CA2693820A1 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
CN101801918A (zh) | 2007-08-02 | 2010-08-11 | 弗·哈夫曼-拉罗切有限公司 | 作为食欲肽受体拮抗剂的单酰胺衍生物 |
CA2694993A1 (en) | 2007-08-15 | 2009-02-19 | Actelion Pharmaceuticals Ltd | 1,2-diamido-ethylene derivatives |
WO2009040730A2 (en) | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
JP2011502146A (ja) | 2007-10-29 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換ジアゼパンオレキシン受容体アンタゴニスト |
DE102007052177A1 (de) | 2007-10-30 | 2009-05-07 | Novega Produktionssysteme Gmbh | Ortungsbake |
EP2058001A1 (en) | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
AU2008339572B2 (en) | 2007-12-21 | 2012-05-10 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
KR101204213B1 (ko) | 2007-12-21 | 2012-11-26 | 에프. 호프만-라 로슈 아게 | 오렉신 수용체 길항제로서의 헤테로아릴 유도체 |
GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
KR20110022631A (ko) | 2008-05-27 | 2011-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 수면 장애 및 다른 장애를 치료하기 위한 방법 및 조성물 |
MX2011000462A (es) | 2008-07-29 | 2011-04-05 | Hoffmann La Roche | Pirrolidin-3-ilmetil-amina como antagonista de orexina. |
AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
US8093255B2 (en) | 2008-10-09 | 2012-01-10 | Glaxo Group Limited | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists |
US8129384B2 (en) | 2008-10-09 | 2012-03-06 | Glaxo Group Limited | Imidazo[1,2-a]pyrazines as orexin receptor antagonists |
US20100267730A1 (en) | 2008-10-09 | 2010-10-21 | Giuseppe Alvaro | Novel compounds |
US8357709B2 (en) | 2008-10-21 | 2013-01-22 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
CA2740190A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
JP2012506379A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 二置換アゼパンオレキシン受容体アンタゴニスト |
CA2739916A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
JP2012506376A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換モルホリンオレキシン受容体アンタゴニスト |
JP2012506374A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
WO2010051238A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | イソニコチンアミドオレキシン受容体アンタゴニスト |
WO2010051237A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
EP2358712A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
MX2011005799A (es) | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
US20100144760A1 (en) | 2008-12-02 | 2010-06-10 | Giuseppe Alvaro | Novel compounds |
GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
US20100214135A1 (en) | 2009-02-26 | 2010-08-26 | Microsoft Corporation | Dynamic rear-projected user interface |
SG175026A1 (en) | 2009-04-24 | 2011-11-28 | Glaxo Group Ltd | 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists |
US20120149723A1 (en) | 2009-08-24 | 2012-06-14 | Romano Di Fabio | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
JP2013502448A (ja) | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | オレキシンアンタゴニストとして用いられるピペリジン誘導体 |
EP2491031B1 (en) | 2009-10-23 | 2013-08-07 | Janssen Pharmaceutica N.V. | Fused heterocyclic compounds as orexin receptor modulators |
EP2491034B1 (en) | 2009-10-23 | 2013-12-18 | Janssen Pharmaceutica, N.V. | Fused heterocyclic compounds as orexin receptor modulators |
ES2735411T3 (es) | 2009-10-23 | 2019-12-18 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina |
EP2491019B1 (en) | 2009-10-24 | 2016-06-29 | Indiana University Research and Technology Corporation | Methods and compositions for panic disorders |
TWI410630B (zh) | 2009-11-10 | 2013-10-01 | Ct Lab Inc | 一種用以治療與食慾素受體1、食慾素受體2、體抑素受體2或多巴胺d2l受體相關之疾病的方法和組合物 |
EP2516425B1 (en) | 2009-12-23 | 2015-09-02 | Jasco Pharmaceuticals LLC | Aminopyrimidine kinase inhibitors |
RU2013132930A (ru) | 2010-12-17 | 2015-01-27 | Тайсо Фармасьютикал Ко., Лтд. | Производное пиразола |
WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
EP2708537A4 (en) | 2011-05-10 | 2014-10-01 | Taisho Pharmaceutical Co Ltd | HETEROAROMATIC CYCLE DERIVATIVE |
US20140228377A1 (en) | 2011-07-05 | 2014-08-14 | Taisho Pharmaceutical Co., Ltd. | Methylpiperidine derivative |
EP2768305A4 (en) | 2011-10-21 | 2015-04-29 | Merck Sharp & Dohme | 2,5-DISUBSTITUTED THIOMORPHOLIN OREXINE RECEPTOR ANTAGONISTS |
EP2811997B1 (en) | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
ES2656972T3 (es) | 2012-02-23 | 2018-03-01 | Vanderbilt University | Análogos de 5-aminotieno [2,3-c] piridazin-6-carboxamida como moduladores alostéricos positivos del receptor de acetilcolina muscarínico M4 |
CN104364238A (zh) | 2012-06-15 | 2015-02-18 | 大正制药株式会社 | 支链烷基杂芳环衍生物 |
JP2014015452A (ja) | 2012-06-15 | 2014-01-30 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体を含有する医薬 |
NZ702647A (en) | 2012-06-15 | 2016-11-25 | Taisho Pharmaceutical Co Ltd | Heteroaromatic methyl cyclic amine derivative |
JP2014111586A (ja) | 2012-11-09 | 2014-06-19 | Taisho Pharmaceutical Co Ltd | ヘテロ芳香環誘導体を含有する医薬 |
EP2925321A4 (en) | 2012-11-27 | 2016-04-27 | Merck Sharp & Dohme | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
JP2016028017A (ja) | 2012-12-13 | 2016-02-25 | 大正製薬株式会社 | フッ素置換ピペリジン化合物 |
JP2014141480A (ja) | 2012-12-28 | 2014-08-07 | Taisho Pharmaceutical Co Ltd | メチルピペリジン誘導体を含有する医薬 |
TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途 |
WO2015018027A1 (en) | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
CA3148326A1 (en) | 2013-12-03 | 2015-06-11 | Intra-Cellular Therapies, Inc. | Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia |
WO2015088865A1 (en) | 2013-12-09 | 2015-06-18 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-methyl orexin receptor antagonists |
JP2015131802A (ja) | 2013-12-13 | 2015-07-23 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 |
JP5930010B2 (ja) | 2013-12-13 | 2016-06-08 | 大正製薬株式会社 | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 |
WO2015095108A1 (en) | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thioether-piperidinyl orexin receptor antagonists |
TW201613891A (en) | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
JP2017100951A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキサゾリジノン及びオキサジナノン誘導体 |
JP2017100950A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキソ複素環誘導体 |
WO2015180060A1 (zh) | 2014-05-28 | 2015-12-03 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
WO2016025669A1 (en) | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
US20160051533A1 (en) | 2014-08-20 | 2016-02-25 | Ladd Research LLC | Diagnosis and pharmacological treatment of seasonal affective disorder and symptoms of seasonality |
GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
CN106349228B (zh) | 2015-07-17 | 2019-07-09 | 广东东阳光药业有限公司 | 取代的喹唑啉酮类化合物及其制备方法和用途 |
GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
MA43468B1 (fr) * | 2016-03-10 | 2020-08-31 | Janssen Pharmaceutica Nv | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 |
GB201820458D0 (en) | 2018-12-14 | 2019-01-30 | Heptares Therapeutics Ltd | Ox1 antagonists |
-
2010
- 2010-10-21 ES ES16163733T patent/ES2735411T3/es active Active
- 2010-10-21 DK DK10773477.4T patent/DK2491038T3/da active
- 2010-10-21 US US13/503,231 patent/US8653263B2/en not_active Ceased
- 2010-10-21 KR KR1020177034279A patent/KR101859400B1/ko active IP Right Grant
- 2010-10-21 RS RS20160501A patent/RS54945B1/sr unknown
- 2010-10-21 BR BR112012010820-4A patent/BR112012010820B1/pt active IP Right Grant
- 2010-10-21 RS RS20190878A patent/RS59004B1/sr unknown
- 2010-10-21 ME MEP-2016-135A patent/ME02437B/me unknown
- 2010-10-21 HU HUE10773477A patent/HUE028650T2/en unknown
- 2010-10-21 PL PL10773477.4T patent/PL2491038T3/pl unknown
- 2010-10-21 SI SI201031214A patent/SI2491038T1/sl unknown
- 2010-10-21 PT PT16163733T patent/PT3093291T/pt unknown
- 2010-10-21 AU AU2010310595A patent/AU2010310595B2/en active Active
- 2010-10-21 CN CN201080058816.XA patent/CN102781942B/zh active Active
- 2010-10-21 EP EP10773477.4A patent/EP2491038B1/en active Active
- 2010-10-21 DK DK16163733.5T patent/DK3093291T3/da active
- 2010-10-21 JP JP2012535384A patent/JP5759470B2/ja active Active
- 2010-10-21 ES ES10773477.4T patent/ES2585806T3/es active Active
- 2010-10-21 NZ NZ599629A patent/NZ599629A/en unknown
- 2010-10-21 KR KR1020127013101A patent/KR20120105449A/ko not_active IP Right Cessation
- 2010-10-21 EP EP19172579.5A patent/EP3581575A1/en active Pending
- 2010-10-21 US US16/391,791 patent/USRE48841E1/en active Active
- 2010-10-21 LT LTEP16163733.5T patent/LT3093291T/lt unknown
- 2010-10-21 MX MX2012004753A patent/MX2012004753A/es active IP Right Grant
- 2010-10-21 CA CA2778484A patent/CA2778484C/en active Active
- 2010-10-21 EA EA201270591A patent/EA022766B1/ru unknown
- 2010-10-21 WO PCT/US2010/053606 patent/WO2011050198A1/en active Application Filing
- 2010-10-21 HU HUE16163733A patent/HUE043962T2/hu unknown
- 2010-10-21 TR TR2019/10327T patent/TR201910327T4/tr unknown
- 2010-10-21 PL PL16163733T patent/PL3093291T3/pl unknown
- 2010-10-21 UA UAA201206182A patent/UA107812C2/ru unknown
- 2010-10-21 KR KR1020177034281A patent/KR101859409B1/ko active IP Right Grant
- 2010-10-21 EP EP16163733.5A patent/EP3093291B1/en active Active
- 2010-10-21 ME MEP-2019-199A patent/ME03452B/me unknown
- 2010-10-21 JO JOP/2010/0362A patent/JO3267B1/ar active
- 2010-10-21 PT PT107734774T patent/PT2491038T/pt unknown
- 2010-10-21 SI SI201031898T patent/SI3093291T1/sl unknown
- 2010-10-22 AR ARP100103874A patent/AR078731A1/es active IP Right Grant
- 2010-10-22 TW TW099136022A patent/TWI481613B/zh active
- 2010-10-22 CL CL2010001162A patent/CL2010001162A1/es unknown
- 2010-10-22 PE PE2010001000A patent/PE20110404A1/es active IP Right Grant
- 2010-10-25 UY UY0001032966A patent/UY32966A/es active IP Right Grant
-
2012
- 2012-04-17 IL IL219234A patent/IL219234A/en active IP Right Grant
- 2012-04-20 NI NI201200062A patent/NI201200062A/es unknown
- 2012-05-11 CO CO12077916A patent/CO6541572A2/es unknown
- 2012-05-17 EC ECSP12011908 patent/ECSP12011908A/es unknown
- 2012-05-23 CR CR20120273A patent/CR20120273A/es unknown
-
2013
- 2013-02-28 HK HK13102554.9A patent/HK1175463A1/zh unknown
- 2013-12-23 US US14/138,941 patent/US9079911B2/en active Active
-
2015
- 2015-06-09 US US14/734,225 patent/US20150335651A1/en not_active Abandoned
- 2015-10-13 AU AU2015242975A patent/AU2015242975B2/en active Active
-
2016
- 2016-07-04 HR HRP20160781TT patent/HRP20160781T1/hr unknown
- 2016-07-05 CY CY20161100629T patent/CY1117743T1/el unknown
- 2016-07-05 SM SM201600216T patent/SMT201600216B/it unknown
-
2017
- 2017-01-24 US US15/413,965 patent/US20170129901A1/en not_active Abandoned
- 2017-05-16 HK HK17104922.6A patent/HK1231463A1/zh unknown
-
2018
- 2018-03-14 JO JOP/2018/0019A patent/JOP20180019B1/ar active
-
2019
- 2019-03-07 AR ARP190100557A patent/AR114667A2/es unknown
- 2019-07-05 HR HRP20191220TT patent/HRP20191220T1/hr unknown
- 2019-07-26 CY CY20191100794T patent/CY1121848T1/el unknown
- 2019-10-15 US US16/601,832 patent/US11059828B2/en active Active
-
2021
- 2021-07-09 US US17/372,168 patent/US11667644B2/en active Active
-
2023
- 2023-06-02 US US18/327,990 patent/US20240109901A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011908A (es) | OCTAHIDROPIRROLO[3,4-c]PIRROLOS DISUSTITUIDOS COMO | |
UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
UY32967A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina | |
CL2012001714A1 (es) | Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras. | |
CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
UY30917A1 (es) | Moduladores 2-aminopiridina del receptor histamina h | |
CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
ECSP14030098A (es) | Formas cristalinas de un modulador del receptor androgénico | |
CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
SV2010003662A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081 | |
CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
NI201100082A (es) | Compuestos de isoindolina para uso en el tratamiento de cáncer. | |
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
UY31340A1 (es) | Moduladores tieno- y furo-pirimidina del receptor de histamina h4 | |
GT201400179A (es) | Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio | |
UY32837A (es) | Uso de la 4-aminopiridina para mejorar el deterioro cognitivo en pacientes con desmielinizacion y otros estados del sistema nervioso | |
UY30921A1 (es) | Tetrahidro-pirazolo-piridinas ligados a carbono como moduladores de catepsina s | |
SV2011003784A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
CL2011003076A1 (es) | Compuestos derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y su uso como inhibidores de la interaccion de las icam con las leucointegrinas y como antagonistas de lfa-1 para tratar una inflamacion o una afeccion inflamatoria tal como infarto al miocardio, accidente cerebrovascular, psoriasis, tiroiditis autoinmunitaria, enfermedad de crohn. | |
CL2010000743A1 (es) | Compuestos derivados cromenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
CL2011002626A1 (es) | Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos. | |
UY32679A (es) | Antagonistas policíclicos de receptores de ácido lisofosfatidico |